Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ARTEMIS-007: A Phase 2 Study to Evaluate Efficacy and Safety of HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer

NCT06052423 is registered in ClinicalTrials.gov with Hansoh BioMedical R&D Company as lead sponsor.

NCT NCT06052423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06052423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ARTEMIS-007: A Phase 2 Study to Evaluate Efficacy and Safety of HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer
Lead sponsor
Hansoh BioMedical R&D Company
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2024
Completion date
June 30, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer (es-sclc)